Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.

Abstract: A method for delivering a nucleic acid to a cell can include exposing sample cells to a composition which includes charged lipids.

Abstract: Fatty esters of oligoesters of a dicarboxylic acid and a polyol retaining at least one free hydroxyl group, particularly of the formula (I): R1—[OR2O—C(O)—R3—(O)C—]m—R4 (I), where R1 is H, a monocarboxylic acid group, or R6O—[C(O)—R3—(O)C]—; R2s are residues of polyols having at least one substituent free hydroxyl; R3s are hydrocarbylene; R4 is —OH, —OM where M is a salt forming metal, amine or ammonium, —OR6, or —OR2O—R7; R5 is C7 to C21 hydrocarbyl; R6 is C8 to C22 hydrocarbyl; R7 is H, or —C(O)R5; and m is 1 to 20; provided that at least one of R1 and R4 is or includes a C8 to C22 group, are surfactants. A range of surfactant properties can be obtained by varying the molecules within these ranges. Especially where R2 is derived from a higher polyol e.g. sorbitol, R3 is C2 to C6, and the fatty terminal group is C8 to C14, the products can be highly water soluble and effective oil in water emulsifiers.

Abstract: A lipid particle can include a cationic lipid. The cationic lipid can include one or more hydrophobic tails, which can include one or more sites of unsaturation. The sites of unsaturation can include cycloalkyl groups, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl groups. The lipid particle is suitable for delivering an active agent.

Abstract: An isotropic or homogeneous emulsion system comprises an oil phase including fat esters of illipe fat and a solubilizer; a non-ionic surfactants; and deionized water; characterized in that the solubilizer is a mixture of polyethyleneglycol-40 hydrogenated castor oil, polysorbate 20 and octoxynol-12.

Abstract: A transdermal delivery system comprising a composition comprising a physiologically active agent and a penetration enhancer wherein the penetration enhancer comprises a combination of (i) an ester of salicylic acid, preferably selected from the C6 to C30 aliphatic ester of salicylic acid and (ii) polyethylene glycol (PEG) of average molecular weight no more than 300.

Abstract: Stents and delivery systems with reduced chemical degradation and methods of sterilizing the same are disclosed.

Abstract: A pharmaceutical composition for application in human and animals, with at least one systemically and/or locally acting, topically applicable active ingredient and with at least one phospholipid, improving the transport of the active ingredient trough the cell membrane and containing a concentration of at least 60% by weight phosphatidylcholine, referring to the phospholipid, is described. The composition shows such a liquid consistency, that it is able to be sprayed as droplets or as a foam, whereas in the composition such a phospholipid is included, that additionally contains oil in a concentration of maximum 7.5% by weight besides the at least 60% by weight phosphatidylcholine.

Abstract: To provide a parakeratosis inhibitor, pore reducing agent and skin roughness preventing/ameliorating agent that exhibit capabilities of parakeratosis inhibition, pore reduction, skin roughness prevention/amelioration, etc., and further provide a skin preparation for external use having these capabilities. There are provide a parakeratosis inhibitor and a pore reducing agent each comprising at least one compound selected from the group consisting of a glycine derivative, an aminodicarboxylic acid derivative, an acylaminodicarboxylic acid derivative, a pyrrolidinecarboxylic acid derivative, a piperidinecarboxylic acid derivative, a hexamethyleneiminecarboxylic acid, a beta-alanine derivative and salts of these derivatives.

Abstract: A block type organopolysiloxane is represented by the following average composition formula (1), wherein each R1 independently represents a monovalent hydrocarbon group having 1 to 12 carbons; R2 represents any of a hydrogen atom, a monovalent hydrocarbon group having 1 to 15 carbons, and a monovalent acyl group having 2 to 7 carbons; R3 represents a hydrogen atom or a monovalent hydrocarbon group having 1 to 4 carbons; X represents a divalent hydrocarbon groups having 2 to 15 carbons; “n” represents an integer of 1 or more; “m” represents an integer of 1 or more; “s” represents an integer of 0 to 100; “t” represents an integer of 0 to 50; “z” represents an integer of 0 to 50; each R4 independently represents a hydrogen atom, a hydroxyl group, an alkoxy group, or an organic group represented by the general formula (2).

Abstract: The present invention relates to a composition for cosmetics including a polyglycerol fatty acid ester, which is an ester of polyglycerol having an average degree of polymerization of 4 to 100 with a fatty acid having 2 to 18 carbon atoms, has a hydroxyl value equal to or less than 15 mgKOH/g, and has a specific gravity at 20° C. of 0.96 to 1.15; a cosmetic which includes the composition for cosmetics; a method for producing an oil-in-water emulsion cosmetic which includes mixing the composition for cosmetics; and a two-separate-layer-type cosmetic, which comprises the composition for cosmetics. The present invention relates to the composition for cosmetics which can be appropriately used in producing a cosmetic giving a highly excellent feel in using and having a very good texture, a cosmetic showing a very high stability over time as an emulsion, and a two-separate-layer-type cosmetic.

Abstract: Self-assembled gel compositions including a gelator, e.g., an enzyme-cleavable gelator, e.g., having a molecular weight of 2500 or less, are described. The self-assembled gel compositions can encapsulate one or more agents. Methods of making the self-assembled gel compositions, and methods of drug delivery using the self-assembled gel compositions are also described.

Abstract: The present invention provides an improved method of administering a medicinal, dental or nutritional agent to a non-human animal, such as a domesticated dog or cat. The method comprises mixing a liquid composition in a mixer at various speeds and pressures for a period of time; pouring the liquid composition onto a conveyor belt propelled by polymer rollers, wherein the polymer rollers allow the components to advance on the conveyor belt without adhering to the belt; evenly distributing the composition on the belt with the use of a knife; heating the composition in one or more hot-air chambers; obtaining a film comprised of the composition; cutting the film into strips; and then administering one or more of the strips to the non-human animal by placing the strip under the tongue of the animal, i.e., by sub-lingual administration.

Abstract: A personal cleansing composition includes a cleansing phase and a benefit phase, the benefit phase having a hydrophobic benefit agent and one or more oligomers derived from metathesis of unsaturated polyol esters and methods relating thereto.

Abstract: A tamper-resistant pharmaceutical dosage form comprising a pharmacologically active ingredient embedded in a prolonged release matrix, which comprises a prolonged release matrix material selected from the group consisting of nonionic acrylic polymers and waxy materials and which provides prolonged release of the pharmacologically active ingredient, resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.

Abstract: Suggested are biocide compositions, comprising (a) 2-Furoic and/or Tetrahydro-2-furoic acid amides; (b) Biocides and optionally (c) Oil components or co-solvents and/or (d) Emulsifiers. The compositions show high solubility for biocides and improved emulsification properties.

Abstract: Methods of cleansing skin comprise the steps of contacting the skin with a cleansing compositions comprising a fatty ester in combination with a lipid, and either rinsing the composition from the skin with water or wiping the composition from the skin with a dry or damp substrate. The cleansing compositions can comprise at least 8%, by weight of the composition, of fatty ester and/or further comprise a nonionic surfactant and less than about 50%, by weight of the composition, of an alcohol solvent such as ethanol, isopropanol, or mixtures thereof. The methods and compositions provide skin cleansing and hydration benefits.

Abstract: The present invention is directed to water-resistant compositions comprising: a reaction product of at least one lactone compound and at least one amine compound chosen from amino alcohol compounds and alkoxylated amine compounds; and optionally, at least one carrier. These water-resistant compositions are capable of providing or acting as a carrier for delivering benefits to various substrates, for example, keratinous substrates such as skin and hair, while at the same time, imparting durable or long lasting hydrophobicity and/or a protective barrier onto said substrates.

Abstract: The present invention is directed to water-resistant compositions comprising: a reaction product of at least one lactone compound and at least one amine compound chosen from alkyl amine compounds and polyamine compounds; and optionally, at least one carrier. These water-resistant compositions are capable of providing or acting as a carrier for delivering benefits to various substrates, for example, keratinous substrates such as skin and hair, while at the same time, imparting durable or long lasting hydrophobicity and/or a protective barrier onto said substrates.

Abstract: The present invention is directed to water-resistant compositions comprising: a reaction product of at least one heterocyclic compound chosen from thiolactone compounds and their thiocarbonyl analogs, and lactam compounds and their thiocarbonyl analogs; and at least one compound having a functional group chosen from an amino group and a hydroxyl group; and optionally, at least one carrier. These water-resistant compositions are capable of providing or acting as a carrier for delivering benefits to various substrates, for example, keratinous substrates such as skin and hair, while at the same time, imparting durable or long lasting hydrophobicity and/or a protective barrier onto said substrates.

Abstract: The present invention is directed to water-resistant compositions comprising: a reaction product of at least one lactone compound and at least one hydroxy compound; and optionally, at least one carrier. These water-resistant compositions are capable of providing or acting as a carrier for delivering benefits to various substrates, for example, keratinous substrates such as skin and hair, while at the same time, imparting durable or long lasting hydrophobicity and/or a protective barrier onto the keratinous substrates.

Abstract: The present invention is directed to water-resistant compositions comprising: a reaction product of at least one lactone compound and at least one alkoxysilane having at least one amino substituent; and optionally, at least one carrier. These water-resistant compositions are capable of providing or acting as a carrier for delivering benefits to various substrates, for example, keratinous substrates such as skin and hair, while at the same time, imparting durable or long lasting hydrophobicity and/or a protective barrier onto said substrates.

Abstract: A pharmaceutical composition comprising a pharmaceutically effective amount of a pharmaceutically active substance and a pharmaceutically acceptable carrier including a cationic excipient, wherein said cationic excipient is a labile ester of betaine and a lipophilic alcohol having at least one primary hydroxyl group. Also, the use of a labile ester of betaine and a lipophilic alcohol having at least a primary hydroxyl group as a cationic excipient in a carrier for a pharmaceutical composition comprising a pharmaceutically active substance.

Abstract: The present invention relates to a solid cosmetic composition comprising, in a cosmetically acceptable medium, (i) a supramolecular compound that may be obtained by reaction between:—at least one oil bearing at least one nucleophilic reactive function chosen from OH and NH2, and—at least one junction group capable of establishing hydrogen bonds with one or more partner junction groups, each pairing of a junction group involving at least three hydrogen bonds, the said junction group bearing at least one isocyanate or imidazole reactive function capable of reacting with the reactive function borne by the oil, the said junction group also comprising at least one unit of formula (I) or (II), (ii) at least one silicone oil, (iii) at least one wax. The invention also relates to a makeup or care process comprising the application of the said composition, especially to the skin or the lips.

Abstract: Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.

Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

Abstract: A rose-like fragrance composition including methyl epijasmonate, provided that a natural jasmine fragrance containing methyl epijasmonate is excluded. The rose-like fragrance composition can also include 2-isopropyl-4-methyl thiazole.

Abstract: Described herein are cyclodextrin-stabilized microemulsion systems useful for increasing the solubility, stability, bioavailability, or safety of an active agent for delivery to the skin. The microemulsions may reduce the occurrence of skin irritation or odor upon application. In certain embodiments, the active agent is substantially insoluble in water. The microemulsions may be formulated as semi-solids, for example creams, or as aerosol or non-aerosol foams. Also described are methods of treating skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive microemulsion.

Abstract: Alkoxylation products, their preparation, compositions comprising these alkoxylation products, and the use thereof as or for producing adhesives and sealants.

Abstract: Provided is an esterification reaction product having high waterproof-film-forming properties, providing shiny feeling, and being excellent in moisture-retaining properties. The esterification reaction product is prepared by esterifying component A: 12-hydroxystearic acid polymer having a degree of polymerization of 7 or more, component B: fatty acid other than 12-hydroxystearic acid polymers, and component C: pentaerythritol.

Abstract: The invention provides formulations that contain an immunogenic or immunostimulatory cargo, delivery moiety and/or lipid, and a lipid that functions to reduce or prevent induction in a subject of an immune response which would otherwise occur when the immunogenic or immunostimulatory cargo, delivery moiety and/or lipid is administered to a subject as a component of an appropriate control formulation lacking the immune response reducing lipid. Specific immune response reducing lipids and uses thereof are further provided.

Abstract: The use of an esteramide compound, alone or as a mixture of the following formula (I): R1OOC-A-CONR2R3??(I) is described, wherein: A is a covalent bond or a methylene group —CH2—, R1 is an optionally substituted hydrocarbon group having from 1 to 36 carbon atoms, R2 and R3, either identical or different, are groups selected from a hydrogen atom and optionally substituted hydrocarbon groups comprising from 1 to 36 carbon atoms, R2 and R3 may form together a ring having the nitrogen atom to which they are bound, said ring being, if need be, substituted and/or having an additional heteroatom and R2 and R3 not being simultaneously hydrogens. Also described, are applications for using the esteramide compound as a solvent, a co-solvent, a coalescence agent, a crystallization inhibitor, a plasticizer or an agent for increasing biological activity.

Abstract: An esteramide compound of the following formula (I): R1OOC-A-CONR2R3??(I) is described, wherein: A is a covalent bond or a methylene group —CH2—; R1 is an optionally substituted, saturated or unsaturated aliphatic or cycloaliphatic hydrocarbon group including from 5 to 36 carbon atoms, R2 and R3, either identical or different, are groups selected from a hydrogen atom, and optionally substituted hydrocarbon groups, preferably including from 1 to 36 carbon atoms, and R2 and R3 not being simultaneously hydrogen atoms. Also described, are applications for using the esteramide compound, notably as a solvent.

Abstract: Biodegradable flavoring agent compositions comprising 1,3-propanediol are provided, and the 1,3-propanediol in the composition is biologically derived. The compositions exhibit a lower anthropogenic CO2 emission profile. Also provided are biodegradable flavoring agent compositions comprising an ester of 1,3-propanediol. In these compositions, the ester can have at least 3% biobased carbon.

Abstract: Methods for enhancing a preference for a product by repetitive use. The method involves formulating a perfume composition into a product, the perfume composition including (I) allyl caproate and (II) ambroxan or geranium oil.

Abstract: To provide an oil-in-water emulsion cosmetic composition obtained by using a polyglycerin fatty acid ester as a surfactant, which has high stability against temperature and is excellent in tactile sensation, and a method for producing the same, the present invention provides an oil-in-water emulsion cosmetic composition, wherein the composition comprises 1) a polyglycerin fatty acid ester, as a surfactant, having a hydroxyl value of 450 to 700, a fatty acid residue having 16 to 18 carbon atoms accounting for 50 to 100% by mass of all constituent fatty acid residues, the polymerization degree of glycerin having specific distribution, 2) an oily component, and 3) water.

Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: Compositions, comprising menthofuran and selected menthol compounds which feature improved flavour and odour properties, are provided and, in addition, the production of compositions, specifically, of emulsions with an improved storage stability.

Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

Abstract: Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.

Abstract: The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof as bitter taste blockers or flavor modulators in, e.g., coffee and coffee flavored foods, beverages and medicaments. Also, the present invention relates to the discovery of a compound that antagonizes numerous different human T2Rs and the use thereof in assays and as a bitter taste blocker in compositions for ingestion by humans and animals.

Abstract: Nanoparticulate formulations for delivery of taxane conjugate prodrug formed from a taxane coupled to a hydrophobic moiety through a glycolate linker are described.

Abstract: The instant invention provides for novel catiomc lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

Abstract: The present invention provides sulfoxide compounds comprising hydrophobic ester or amide moieties such that the compounds have surfactant properties. Also provided are methods for using the sulfoxide compounds or mixtures of the sulfoxide compounds in a variety of applications.

Abstract: Disclosed is a stellate cell-specific drug carrier comprising a stellate cell-specific amount of a retinoid derivative and/or a vitamin A analogue, and a drug carrier component other than the retinoid derivative and/or a vitamin A analogue. Also disclosed in a medicine comprising the stellate cell-specific drug carrier, and a drug in an amount effective for controlling the activity or growth of stellate cells.

Abstract: The present invention relates to compositions, including pharmaceutical compositions for oral administration, comprising: at least one therapeutically active agent; at least one surface active agent; at least one ester of poly-carboxylic acid and/or at least one ester of an aromatic carboxylic acid; and a non-aqueous medium, for use in the gastric absorption of said at least one therapeutically active agent of the composition and methods of oral administration of at least one therapeutically active agent utilizing compositions of the invention.

Abstract: What is described are macrocyclic compounds formed by reaction of a cyclic compound, which contains an amine, with an epoxide. The macrocyclic compound has the following structure: When substituents R and R? that are hydrophobic substituents, the macrocyclic compound functions as a lipid and is compatible with lipid systems, including liposomes and lipid particles. When present in certain lipid systems, the macrocyclic compound enhances the ability of the lipid system to facilitate delivery of therapeutic molecules to target cells in a mammalian subject.

Abstract: A PEG based hydrogel and a procedure for its topical application to the surface of the pia mater of the spinal cord that can be used for intrathecal delivery of diverse drug and biomolecular therapies for the treatment of traumatic central nervous system injuries and disorders including spinal cord injury (SCI), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are provided. This “painting of the pia” with biofunctionalized hydrogel material may be used as a prelude strategy in the therapeutic management of these CNS disorders. The strategy may be designed to create a microenvironment within the damaged regions of the spinal cord that is more conducive to the successful application of subsequent regeneration based treatments such as cell replacement therapies or endogenous regeneration and plasticity stimulation via application of growth factors or gene therapy.

Abstract: The present invention relates to novel benzotriazoles and to novel topical compositions comprising these benzotriazoles. Furthermore, the invention relates to the use of the novel benzotriazoles as photostabilizer and solubiliser for dibenzoyl-methane derivatives such as Butyl Methoxydibenzoylmethane. In one aspect the invention relates to novel benzotriazoles of formula (Ia) wherein R2 is hydrogen; C1-30alkyl; C1-5alkoxy; C1-5alkoxycarbonyl; C5-7cycloalkyl; C6-10aryl or aralkyl; R3 is hydrogen; C1-5alkyl; C1-5alkoxy or halogen, preferably hydrogen or Cl; R4 is hydrogen or C1-5alkyl; R5 is C1-30alkyl or C5-10cycloalkyl.

Abstract: Hydrogels that may be used for treating peripheral nerves and related methods are provided. Synthetic hydrogel sealants, methods of forming synthetic hydrogel sealants, and the use of synthetic hydrogel sealants are provided.